Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Could tweaking methodologies improve amyloid diagnosis and tracking?
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
A global effort to combat dementia has been conducting a yearlong series of events. Alzforum spoke with Dennis Gillings, who chairs the new World Dementia Council.
Researchers will have full access to a gargantuan genetic meta-analysis on the newly revamped PDGene database.
New data strengthens the evidence that dementia risk is dropping in developed countries, possibly due to better education and heart health.
In mouse models, Aβ aggregates injected into the belly invade the brain, as do prion seeds.
Lifestyle changes to evade dementia, such as healthy eating and exercise, made a strong showing at the Alzheimer’s Association International Conference in Copenhagen, Denmark.
Signals emanating from the prefrontal cortex play a role in forming memories in the hippocampus, a study reports. The finding could have implications for Alzheimer’s.
Researchers have modeled a motor neuron in silico to show how energy shortage could lead to its degeneration in amyotrophic lateral sclerosis.
An active immunotherapy is coming to the fore as researchers continue to try novel therapies.
Does a tau-based early diagnosis look more likely?
In a large observational study, high blood pressure in midlife correlated with faster cognitive decline over the next two decades.